Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia

This publication has 7 references indexed in Scilit:

• Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial
  Bone Marrow Transplantation, 2004
• Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia
  Blood, 2003
• Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis
  Bone Marrow Transplantation, 2003
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
  Leukemia, 2002
• Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
  Blood, 2002
• Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia
  British Journal of Haematology, 2000
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996